Insulin resistance signaling proteins

Insulin resistance signaling proteins refer to the network of molecules involved in the transduction of the insulin signal from the cell surface to intracellular effectors [1]. Key components include the insulin receptor (INSR), which possesses intrinsic tyrosine kinase activity, and the insulin receptor substrate (IRS) family of adaptor proteins [2][3]. Upon insulin binding, these proteins activate downstream pathways such as the PI3K/AKT pathway, which is critical for the translocation of GLUT4 glucose transporters to the plasma membrane [1][4]. In pathological states, insulin resistance occurs when these signaling nodes are inhibited by factors like pro-inflammatory cytokines, fatty acids, or cellular stress, often involving inhibitory serine phosphorylation of IRS proteins [4][5]. This disruption leads to impaired glucose uptake in muscle and adipose tissue and failure to suppress gluconeogenesis in the liver [1]. Pharmacological agents like thiazolidinediones (TZDs) act as PPAR-gamma agonists to improve the expression and function of these signaling components [6]. Other treatments, such as metformin, indirectly influence this pathway by activating AMPK, which enhances insulin sensitivity [7]. Understanding these proteins is vital for developing therapies for type 2 diabetes, metabolic syndrome, and associated cardiovascular complications [1][5].

Other names

Insulin signaling pathwayInsulin receptor signaling cascadeInsulin-mediated metabolic signaling

Drugs targeting these proteins work by activating the insulin receptor tyrosine kinase, enhancing the recruitment of insulin receptor substrates (IRS), stimulating the PI3K/AKT signaling cascade to promote GLUT4 translocation, or inhibiting negative regulators like PTP1B and SOCS proteins to restore insulin sensitivity [1][4][5].